A phase I dose-escalation, pharmacokinetic and pharmacodynamic evaluation of intravenous LY2275796 in patients with advanced cancer.

Trial Profile

A phase I dose-escalation, pharmacokinetic and pharmacodynamic evaluation of intravenous LY2275796 in patients with advanced cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2012

At a glance

  • Drugs ISIS EIF4ERx (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)
    • 03 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top